Beyond Air Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Air Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

revenues by 157% to $1.8 million, compared with $0.7 million for the fiscal quarter ended June 30, 2024

a national group purchasing agreement for therapeutic gases by Premier, Inc., which has more than 4,350 member hospitals and health systems

revenue guidance of $12-$16 million for the full fiscal year 2026

call at 4:30 p.m. ET today, August 12th

CITY, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) - Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"),

a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives

of patients, today announced its financial results for fiscal first quarter ended June 30, 2025, and provided a corporate update.

are driving strong market adoption of LungFit PH as we continue to break down barriers and expand our global distribution network,"

said Steve Lisi, Chairman and Chief Executive Officer. "This momentum in our business resulted in strong sequential revenue growth

of approximately 50%, to $1.8 million compared with $1.2 million for the March 31, 2025 quarter. Looking ahead, we expect the trajectory

of our sales to support sustained double-digit sequential revenue growth and reaffirm our FY 2026 revenue guidance of $12 to $16 million."

Execution, Recent Highlights and Upcoming Milestones

Cancer - Solid Tumor Program - clinical stage development of an intratumoral ultra-high concentration Nitric Oxide (UNO) technology

as a gas delivery of NO at high concentrations to tumors to induce an immune response.

- Autism Spectrum Disorder (ASD) Program - developing neuronal nitric oxide synthase (nNOS) inhibitors for the treatment of autism

spectrum disorder ("ASD") and other neurological conditions.

Results for the Fiscal Quarter Ended June 30, 2025

for the fiscal quarter ended June 30, 2025 increased 157% to $1.8 million, compared with $0.7 million for the fiscal quarter ended June

30, 2024. Gross Profit of $0.2 million was recognized for the quarter ended June 30, 2025, compared with a gross loss of $0.3 million

for the quarter ended June 30, 2024. The Gross Profit increase was due to increasing revenues, partially offset by depreciation of additional

and development expenses for the fiscal quarter ended June 30, 2025 were $3.1 million compared with $6.0 million for the fiscal quarter

ended June 30, 2024. The decrease of $2.9 million was primarily attributed to a decrease in salaries, stock-based compensation costs,

clinical and pre-clinical studies expenses, professional fees and Gen II device development costs.

general and administrative expenses for the quarters ended June 30, 2025 and June 30, 2024 were $4.7 million and $7.2 million, respectively.

The decrease of $2.5 million was attributed primarily to a reduction in salaries, stock-based compensation costs, marketing and advertising

costs and legal fees.

expense for the quarter ended June 30, 2025 was $(0.5) million compared with other income of $0.5 million for the quarter ended June

30, 2024. The increase in expense of $(1.0) million was mainly due to a prior period gain associated with the change in fair value of

the derivative liability of $1.0 million.

loss attributed to common stockholders of Beyond Air, Inc. for the quarter ended June 30, 2025 was ($7.7) million or a loss of ($1.53)

per share, basic and diluted, compared to a net loss attributed to common stockholders of Beyond Air, Inc. for the fiscal quarter ended

June 30, 2024 of ($12.2) million or a loss of ($5.32) per share, basic and diluted. The per share results were calculated to reflect

the Company's 1-for-20 reverse stock split, which became effective on July 14, 2025. As a reminder, The Company implemented the

reverse stock split to regain compliance with the Nasdaq Listing Rule 5550(a)(2). The Nasdaq has since notified the Company that it is

now in compliance with all listing rules.

cash burn in the fiscal quarter ended June 30, 2025 was $4.7 million.

of June 30, 2025, the Company reported cash, cash equivalents, and marketable securities of $6.5 million, and total long-term debt outstanding

of $11.6 million. Debt repayment does not begin until October 2026.

Guidance for Fiscal Year 2026

The Company reaffirmed its revenue guidance of $12 to $16 million for the fiscal year ending

August 12th @ 4:30 PM ET

Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and

exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid

tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term

neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials

for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria

Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism

spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating

ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more

information, visit www.beyondair.net.

Air's LungFit is a cylinder-free, phasic flow generator and delivery system designated as a medical device by the U.S. Food and

Drug Administration (FDA). The ventilator-compatible version of the device can generate NO from ambient air on demand for delivery to

the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders,

providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall

safety by eliminating NO2 purging steps, and offering other operational benefits.

can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting

(e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g., NTM). With the elimination of cylinders,

Beyond Air intends to offer NO treatment in the home setting.

Air's LungFit PH is approved for commercial use in the United States, European Union, and many other countries around the world.

Beyond Air's other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not

suggesting NO use over 80 ppm or use at home.

Persistent pulmonary hypertension of the newborn (PPHN) is a lethal condition and secondary to failure of normal circulatory

transition at birth. It is a syndrome characterized by elevated pulmonary vascular resistance (PVR) that causes labile hypoxemia due

to decreased pulmonary blood flow and right-to-left shunting of blood. Its incidence has been reported as 1.9 per 1,000 live births (0.4-6.8/1000

live births) with mortality rate ranging between 4-33%. This syndrome complicates the course of about 10% of infants with respiratory

failure and remains a source of considerable morbidity and mortality. NO gas is a vasodilator, is approved in dozens of countries to

improve oxygenation and reduces the need for extracorporeal membrane oxygenation (ECMO) in term and near-term (>34 weeks gestation)

neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction

with ventilator support and other appropriate agents.

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc., is a development-stage biopharmaceutical and medical

device company utilizing (UNO via a proprietary delivery platform to treat primary tumors and prevent metastatic disease. Nitric oxide

at ultra-high concentrations has been reported to show anticancer properties and to potentially serve as a chemosensitizer and radiotherapy

enhancer. A first-in-human study is underway in subjects with solid tumors. The Company is conducting preclinical studies of UNO in multiple

solid tumor models to inform additional treatment protocols. For more information, visit www.beyondcancer.com.

is at the forefront of developing innovative treatments for neurodevelopmental and neurodegenerative disorders. The company specializes

in creating therapies based on small molecules that cross the blood-brain barrier to regulate Nitric Oxide (NO) levels in the brain.

Preclinical studies conducted by NeuroNOS have demonstrated that NO is present at elevated levels in children with Autism Spectrum Disorder

(ASD) and adults suffering from brain-related diseases such as Alzheimer's and brain cancers. The company's research has

shown that managing NO levels in the brain is crucial for maintaining normal brain function. By leveraging this groundbreaking science,

NeuroNOS aims to bring transformative therapies to those affected by these challenging conditions, ultimately improving individuals'

lives. Through collaborations with leading research institutions and experts in the field, the company is committed to advancing medical

innovation and delivering life-changing treatments. For more information, please visit https://www.neuro-nos.com.

press release contains "forward-looking statements" concerning the potential safety and efficacy of inhaled nitric oxide

and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and

the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric

oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings,

business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words "appears,"

"expects," "plans," "anticipates," "believes" "expects," "intends,"

"looks," "projects," "goal," "assumes," "targets" and similar expressions

and/or the use of future tense or conditional constructions (such as "will," "may," "could," "should"

and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking

statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking

statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could

cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking

statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance.